Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers
Anticancer Research · 2023
DOI: 10.21873/anticanres.16370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2023. Verfasst von Tomoko Ueda und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hyogo Medical University Hospital, Hyogo, Japan. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Ovarian Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND/AIM: The clinical benefits of comprehensive genomic profiling (CGP) of tumours in patients with gynaecological cancers remain unknown. We investigated the utility of CGP in assessing patient survival and its efficacy in detecting hereditary cancers in gynaecological patients. PATIENTS AND METHODS: We retrospectively analysed the medical records of 104 gynaecological patients who underwent CGP between August 2018 and December 2022. The detection of actionable and accessible genomic alterations and administration of targeted therapy, as recommended by the molecular tumour board (MTB), were assessed. The overall survival (after second-line treatment in cervical and endometrial carcinomas and after platinum-resistant recurrence in ovarian carcinoma) was compared between patients with or without administration of MTB-recommended genotype-matched therapy. Germline findings were assessed using a variant allele frequency-tumour content graph. RESULTS: Among 104 patients, actionable and accessible genomic alterations were observed in 53 patients. Matched therapy was applied in 21 patients, comprising administration of repurposing itraconazole (n=7), immune checkpoint inhibitors (n=7), poly (ADP-ribose) polymerase inhibitors (n=5), and others (n=2). The median overall survival of patients receiving and not receiving matched therapy were 19.3 months and 11.2 months, respectively (p=0.036, hazard ratio=0.48). Among 12 patients with hereditary cancers, 11 patients were previously undiagnosed. Seven patients had hereditary breast and ovarian cancer, and five had other cancer. CONCLUSION: The implementation of CGP testing prolonged overall survival in gynaecological cancer as well as provided an opportunity for genetic counselling for newly-diagnosed patients with hereditary cancers and their families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Hyogo Medical University Hospital, Hyogo, Japan.
- Department of Obstetrics and Gynecology, Hyogo Medical University Hospital, Hyogo, Japan; tsuba@hyo-med.ac.jp.
- Department of Clinical Genetics, Hyogo Medical University Hospital, Hyogo, Japan.
- Cancer Center, Hyogo Medical University Hospital, Hyogo, Japan.
- Department of Breast and Endocrine Surgery, Hyogo Medical University Hospital, Hyogo, Japan.
- Department of Surgical Pathology, Hyogo Medical University Hospital, Hyogo, Japan.
Zitieren
APA
Ueda, T., Tsubamoto, H., Takimoto, Y., Isono-Taniguchi, R., Narita, S., Nakagawa, K., Wakimoto, Y. U., Nishimura, Y., Muroi, Y., Nagahashi, M., Hirota, S., Sawai, H., & Shibahara, H. (2023). Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers. Anticancer Research. https://doi.org/10.21873/anticanres.16370
Vancouver
Ueda T, Tsubamoto H, Takimoto Y, Isono-Taniguchi R, Narita S, Nakagawa K, et al. Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers. Anticancer Research. 2023. doi:10.21873/anticanres.16370
BibTeX
@article{Ueda2023,
author = {Ueda, Tomoko and Tsubamoto, Hiroshi and Takimoto, Yumi and Isono-Taniguchi, Roze and Narita, Sachiyo and Nakagawa, Kohei and Wakimoto, Y U and Nishimura, Yumiko and Muroi, Yoshiko and Nagahashi, Masayuki and Hirota, Seiichi and Sawai, Hideaki and Shibahara, Hiroaki},
title = {Comprehensive Genomic Profiling Detects Hereditary Cancers and Confers Survival Advantage in Patients With Gynaecological Cancers},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16370}
}
EUVIMED